Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO and President Jack Zhang, along with CFO Bill Peters, will deliver a presentation on Wednesday, January 15th, 2025, at 11:15 am PST.
The presentation will be accessible through a webcast on Amphastar's website at http://ir.amphastar.com. Interested parties can access the webcast recording for 30 days following the presentation.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il CEO e Presidente Jack Zhang, insieme al CFO Bill Peters, terranno una presentazione mercoledì 15 gennaio 2025, alle 11:15 PST.
La presentazione sarà accessibile tramite un webcast sul sito web di Amphastar all'indirizzo http://ir.amphastar.com. Le parti interessate potranno accedere alla registrazione del webcast per 30 giorni dopo la presentazione.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. El CEO y Presidente Jack Zhang, junto con el CFO Bill Peters, ofrecerán una presentación el miércoles 15 de enero de 2025, a las 11:15 a.m. PST.
La presentación estará disponible a través de un webcast en el sitio web de Amphastar en http://ir.amphastar.com. Las partes interesadas podrán acceder a la grabación del webcast durante 30 días después de la presentación.
암파스타 제약 (NASDAQ:AMPH)는 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO이자 회장인 잭 장(Jack Zhang)과 CFO인 빌 피터스(Bill Peters)는 2025년 1월 15일 수요일 오전 11시 15분 PST에 발표를 할 예정입니다.
발표는 암파스타 웹사이트(http://ir.amphastar.com)를 통해 웹캐스트로 확인할 수 있습니다. 관심 있는 분들은 발표 후 30일 동안 웹캐스트 녹화를 접속할 수 있습니다.
Amphastar Pharmaceuticals (NASDAQ:AMPH) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Le PDG et Président Jack Zhang, ainsi que le CFO Bill Peters, présenteront une présentation le mercredi 15 janvier 2025, à 11h15 PST.
La présentation sera accessible par le biais d'un webcast sur le site web d'Amphastar à l'adresse http://ir.amphastar.com. Les parties intéressées pourront accéder à l'enregistrement du webcast pendant 30 jours suivant la présentation.
Amphastar Pharmaceuticals (NASDAQ:AMPH) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. CEO und Präsident Jack Zhang wird zusammen mit CFO Bill Peters eine Präsentation am Mittwoch, den 15. Januar 2025, um 11:15 Uhr PST halten.
Die Präsentation wird über einen Webcast auf der Website von Amphastar unter http://ir.amphastar.com zugänglich sein. Interessierte Parteien können die Aufzeichnung des Webcasts 30 Tage nach der Präsentation abrufen.
- None.
- None.
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
About Amphastar:
Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.
The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST®, Amphadase®, Cortrosyn®, REXTOVY® and BAQSIMI® are the property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST® or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
CONTACT:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is Amphastar Pharmaceuticals (AMPH) presenting at the J.P. Morgan Healthcare Conference 2025?
How long will the AMPH J.P. Morgan Healthcare Conference presentation webcast be available?
Where can I watch Amphastar's (AMPH) J.P. Morgan Healthcare Conference presentation?
Who will be presenting for Amphastar (AMPH) at the 2025 J.P. Morgan Healthcare Conference?
